SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in theHepatocellular Carcinoma Mouse Model

Abstract

Our results show that SHR6390 exhibited potent anti-proliferative activity against HCC in a dose-dependent manner. SHR6390 combined with cabozantinib exhibited more potent inhibition of cell viability, migration and invasion. In terms of potential mechanisms, we found that cabozantinib could lead to phosphorylation of Rb, which was reduced in SHR6390 and combined groups. SHR6390 monotherapy inhibited the growth of subcutaneous HCC tumors, besides, the combination treatment with SHR6390 and cabozantinib exerted synergistic anti-tumor activity <i>in vivo</i> Conclusion: SHR6390 is effective against HCC, monotherapy or combined with cabozantinib.